Clinical Utility of Tremelimumab/Durvalumab as First-line Treatment for Unresectable Hepatocellular Carcinoma: Serum Cytokine Profile Insights
{{output}}
Background/aim: Although immunotherapies such as atezolizumab plus bevacizumab (Ate/Bev) and tremelimumab plus durvalumab (Tre/Dur) are recommended as first-line treatments for unresectable hepatocellular carcinoma (uHCC), the cl... ...
